首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   114篇
  免费   9篇
  国内免费   3篇
儿科学   2篇
妇产科学   6篇
基础医学   11篇
临床医学   6篇
内科学   55篇
神经病学   2篇
特种医学   1篇
外科学   9篇
综合类   18篇
预防医学   9篇
药学   4篇
中国医学   2篇
肿瘤学   1篇
  2023年   3篇
  2022年   4篇
  2021年   5篇
  2020年   5篇
  2019年   5篇
  2018年   3篇
  2016年   9篇
  2015年   4篇
  2014年   14篇
  2013年   11篇
  2012年   7篇
  2011年   13篇
  2010年   7篇
  2009年   7篇
  2008年   9篇
  2007年   12篇
  2006年   4篇
  2005年   3篇
  2004年   1篇
排序方式: 共有126条查询结果,搜索用时 15 毫秒
1.

Background and aims

Leptin (LPT) is associated with unfavourable cardio-metabolic risk profile. Although a number of studies have found a positive association between LPT and insulin resistance (IR), no observational study has evaluated a prospective association to detect a predictive role of LPT in IR. Therefore, the aim of this study was to estimate the role of LPT on the incidence of IR in an 8-year follow-up of a sample of adult men (The Olivetti Heart Study).

Methods and results

The study included 527 not diabetic men without IR (homeostasis model assessment - HOMA index < 2.77 UI) at baseline. Baseline LPT was significantly and positively associated with HOMA index, body mass index (BMI), waist circumference and blood pressure. At the end of the 8-year follow-up period, a positive and significant association was detected between baseline LPT and changes in HOMA index (r = 0.25, p < 0.01) and incidence of IR (OR: 2.6, 95%CI: 1.9–3.4). This trend was also confirmed after adjustment for potential confounders. In addition, the predictive value of LPT was found in subjects who had not experienced any weight increase over the years, and for normal weight and excess body weight participants, separately.

Conclusions

The results of this prospective study suggest a predictive role of circulating LPT levels on a reduction of insulin sensitivity over time, independently of main potential confounders, in non-diabetic men without IR at baseline. In addition, in normal weight individuals, LPT levels were associated with development of IR.  相似文献   
2.

Aims

Type 1 diabetic patients (T1DM) experience a higher cardiovascular disease and mortality risk than controls. We investigated whether visceral adipose tissue (VAT) contributes to coronary artery calcifications (CAC) and cardiac dysfunction in T1DM.

Methods

A cross-sectional study of 118 T1DM patients without a history of cardiovascular disease (men/women: 68/50, age 46 ± 12 years, HbA1c 7.6 ± 0.9%, BMI 25.8 ± 4.1 kg/m2) was conducted. CAC and VAT were measured using a CT scan. CAC was scored using the Agatston method. Cardiac functional abnormalities were assessed by echocardiography.

Results

CAC scored ≥ 10 in 42% of patients. Systolic function was normal in all, but diastolic dysfunction was present in 75%. Forty-six percent had VAT  100 cm2. CAC score  10 occurred more often in subjects with VAT  100 cm2 (54% vs 31%; p = 0.01). Age (OR = 1.10; p < 0.0001), diabetes duration (OR = 1.10; p = 0.008), gender (OR = 4.28; p = 0.016), LDL-cholesterol (OR = 1.03; p = 0.009) and metabolic syndrome (OR = 5.79; p = 0.005) were independently associated with a CACS  10. Subjects with CACS  10 were more prone to have diastolic dysfunction (84 vs 54%; p = 0.03). Factors independently associated with diastolic dysfunction were age (OR = 1.11; p = 0.002), waist circumference (OR = 1.10; p = 0.016) and VAT (OR = 0.99; p = 0.035).

Conclusions

Excess VAT in T1DM, present in 46%, is associated with diastolic dysfunction and CAC, present in respectively 75% and 42% of patients. Timely detection might improve future cardiovascular risk.  相似文献   
3.
4.
《Journal of cardiology》2014,63(4):308-312
BackgroundResistin is a peptide hormone that is secreted from lipid cells and is linked to type-2 diabetes, obesity, and inflammation. Being an important adipocytokine, resistin was proven to play an important role in cardiovascular disease. We compared resistin levels in patients with and without atrial fibrillation (AF) to demonstrate the relationship between plasma resistin levels and AF.MethodOne hundred patients with AF and 58 control patients who were matched in terms of age, gender, and risk factors were included in the trial. Their clinical risk factors, biometric measurements, echocardiographic work up, biochemical parameters including resistin and high-sensitivity C-reactive protein (hs-CRP) levels were compared.ResultsIn patients with AF, plasma resistin levels (7.34 ± 1.63 ng/mL vs 6.67 ± 1.14 ng/mL; p = 0.003) and hs-CRP levels (3.01 ± 1.54 mg/L vs 2.16 ± 1.28 mg/L; p = 0.001) were higher than control group. In subgroup analysis, resistin levels were significantly higher in patients with paroxysmal (7.59 ± 1.57 ng/mL; p = 0.032) and persistent AF (7.73 ± 1.60 ng/mL; p = 0.006), but not in patients with permanent AF subgroups (6.86 ± 1.61 ng/mL; p = 0.92) compared to controls. However, hs-CRP levels were significantly higher only in permanent AF patients compared to control group (3.26 ± 1.46 mg/L vs 2.16 ± 1.28 mg/L; p = 0.02). In multivariate regression analysis using model adjusted for age, gender, body mas index, hypertension, diabetes mellitus, and creatinine levels, plasma resistin levels [odds ratio (OR): 1.30; 95% confidence interval (CI): 1.01–1.70; p = 0.04] and hs-CRP levels (OR: 1.44; 95% CI: 1.12–1.86; p = 0.004) were the only independent predictors of AF.ConclusionThe elevated levels of plasma resistin were related to paroxysmal AF group and persistent AF group, but not to permanent AF group.  相似文献   
5.
AimsThis study aimed to summarize earlier studies on the effects of dairy consumption on inflammatory biomarkers in adults and to quantify these effects through meta-analysis.Data synthesisA comprehensive search of all relevant articles, published up to December 2019 indexed in PubMed, ISI (Institute for Scientific Information), EmBase, Scopus, and Google Scholar was done using relevant keywords. Randomized controlled trials (RCTs) that examined the effect of dairy products consumption, compared with low or no dairy intake, on inflammatory biomarkers in adults were included. Overall, 11 RCTs with 663 participants were included in this meta-analysis. We found that high consumption of dairy products, compared with low or no dairy intake, might significantly reduce CRP [weighed mean difference (WMD): −0.24 mg/L; 95% CI, −0.35, −0.14], TNF-α (WMD:- 0.66 pg/mL; 95% CI, −1.23, −0.09), IL-6 (WMD: −0.74 pg/mL; 95% CI, −1.36, −0.12), and MCP concentrations (WMD: −25.58 pg/mL; 95% CI, −50.31, −0.86). However, when the analyses were confined to cross-over trials, no such beneficial effects of dairy intake on inflammation were observed. In addition, high dairy intake might result in increased adiponectin levels (WMD: 2.42 μg/mL; 95% CI, 0.17, 4.66). No significant effect of dairy consumption on serum leptin (WMD: −0.32 ng/mL; 95% CI, −3.30, 2.65), ICAM-1 (WMD: −3.38 ng/ml; 95% CI, −15.57, 8.96) and VCAM-1 (WMD: 3.1 ng/mL; 95% CI, −21.38, 27.58) levels was observed.ConclusionsIn summary, the current meta-analysis indicated that dairy intake might improve several inflammatory biomarkers in adults. In most subgroups without heterogeneity, effects tended to be null. Study design and participants’ age were the main sources of heterogeneity. More research, with a particular focus on fat content of dairy foods, is recommended.  相似文献   
6.

Aims/Introduction

It is thought that adipocytokines contribute to the increased risk of vascular complications in type 2 diabetes. However, there is still limited information on the relationship between microangiopathies and adipocytokines, such as adiponectin, leptin and tumor necrosis factor‐α (TNF‐α) in patients with type 2 diabetes.

Materials and Methods

The present study examined the relationship between fasting serum adiponectin, leptin, and TNF‐α levels and microangiopathies in Korean type 2 diabetes. A total of 153 patients were recruited and evaluated for diabetic nephropathy, retinopathy and neuropathy. Serum adiponectin, TNF‐α and leptin levels were measured.

Results

Serum adiponectin levels were significantly lower in patients with nephropathy than in those without nephropathy (P = 0.017), and were significantly higher in patients with retinopathy or neuropathy than those without retinopathy or neuropathy (P = 0.01 and P = 0.002, respectively). The mean levels of leptin were significantly higher in patients with neuropathy than in those without neuropathy (P = 0.002). The mean levels of TNF‐α were not significantly different according to any of the three microangiopathies. Multivariate logistic regression analysis showed that the odds ratio for the presence of neuropathy in the highest tertile of adiponectin was 4.3 (95% confidence interval 1.59–11.62), as compared with the patients in the lowest tertile of adiponectin level.

Conclusions

Levels of adipocytokines were significantly different according to the presence of each microangiopathy. In particular, higher serum adiponectin was independently associated with increased odds for the presence of neuropathy. Future prospective studies with larger numbers of patients are required to establish a direct relationship between plasma adipocytokine concentrations and the development or severity of diabetic microangiopathies.  相似文献   
7.
胃旁路术在平稳减肥的同时能增加胰岛素敏感性,改善糖代谢紊乱。其机制包括胃减容以减少摄入,前肠旁路致胃肠-胰岛轴改变引起多种胃肠激素如ghrelin、胰升糖素样肽-1(GLP-1)、葡萄糖依赖性促胰岛素多肽、多肽YY等变化改善了胰岛素的分泌和(或)活性,脂肪细胞因子的改变如脂联素水平升高、瘦素及酰化刺激蛋白降低和一些炎性反应因子如C反应蛋白、白细胞介素-6(IL-6)的变化等。  相似文献   
8.
脂联素及其受体研究进展   总被引:1,自引:1,他引:1  
脂联素(adiponectin)是来源于脂肪组织的脂肪细胞因子之一,具有抗炎、抗糖尿病、抗动脉粥样硬化和增敏胰岛素的作用。脂联素的这些效应必须通过脂联素受体1(AdipoR1)和AdipoR2的介导。近年的研究发现,AdipoR1在骨骼肌中有丰富表达,AdipoR2主要在肝中表达;AdipoR1和AdipoR2也在人和鼠的胰岛β细胞中表达,其水平与肝中类似,比骨骼肌更高;AdipoR1和AdipoR2也可在单核细胞和巨噬细胞中表达。过氧化物酶体增殖物激活受体-α(PPAR-α)、PPAR-γ和肝X受体(LXR)的激动剂以及生长激素(GH)可影响脂联素受体的表达和调节。  相似文献   
9.
妊娠糖尿病的研究进展   总被引:2,自引:0,他引:2  
王君  李红星 《医学综述》2012,18(3):429-431
妊娠糖尿病的患病率和病死率逐年增加,严重影响母婴的健康,但其发病机制至今尚未明确。临床研究发现多种因素促成了妊娠糖尿病的发生,包括胰岛素抵抗、胰岛β细胞功能缺陷、妊娠激素、炎性因子和脂肪细胞因子、遗传等。尤其近年关于炎性因子和脂肪因子的大量研究,为妊娠糖尿病的发病机制及对妊娠糖尿病的筛查和诊断方法的归纳与早期发现妊娠糖尿病提供了有力的依据。  相似文献   
10.
Aims/hypothesis The adipokine adiponectin has insulin-sensitising, anti-atherogenic and anti-inflammatory properties. Recently, the genes for mouse and human adiponectin receptor-1 (ADIPOR1) and -2 (ADIPOR2) have been cloned. The aim of this study was to investigate whether genetic variants of the genes encoding ADIPOR1 and ADIPOR2 play a role in human metabolism.Materials and methods We screened ADIPOR1 and ADIPOR2 for polymorphisms and determined their association with glucose metabolism, lipid metabolism, an atherogenic lipid profile and inflammatory markers in 502 non-diabetic subjects. A subgroup participated in a longitudinal study; these subjects received diet counselling and increased their physical activity.Results We identified six variants of ADIPOR1 and seven variants of ADIPOR2. A single-nucleotide polymorphism (SNP) in the putative promoter region 8503 bp upstream of the translational start codon (–8503 G/A) of ADIPOR1 (frequency of allele A=0.31) was in almost complete linkage disequilibrium with another SNP (–1927 T/C) in intron 1. Subjects carrying the –8503 A and –1927 C alleles had lower insulin sensitivity, as estimated from a 75 g OGTT (p=0.04) and determined during a euglycaemic clamp (n=295, p=0.04); they also had higher HbA1c levels (p=0.02) and, although the difference was not statistically significant, higher liver fat (n=85, determined by proton magnetic resonance spectroscopy, p=0.056) (all p values are adjusted for age, sex and percentage of body fat). In the longitudinal study (n=45), the –8503 A and –1927 C alleles were associated with lower insulin sensitivity (p=0.03) and higher liver fat (p=0.02) at follow-up compared with the –8503 G and –1927 T alleles, independently of basal measurements, sex and baseline and follow-up percentage of body fat.Conclusions/interpretation The present findings suggest that the –8503 G/A SNP in the promoter or the –1927 T/C SNP in intron 1 of ADIPOR1 may affect insulin sensitivity and liver fat in humans.Electronic Supplementary Material Supplementary material is available for this article at .  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号